Sunitinib remains a cornerstone for patients with imatinib-resistant GIST, with a well-characterized safety profile and documented efficacy in targeting VEGFR, PDGFR, and KIT-driven pathways. Here, KDR is linked to gastrointestinal stromal tumor.